Moxifloxacină Rompharm

Moxifloxacin, the active ingredient in Moxifloxacină Rompharm, is a fluoroquinolone antibiotic presented as an injectable solution for intravenous use. It treats a broad range of serious bacterial infections in adult patients, including community‑acquired pneumonia, intra‑abdominal infections, and complicated skin and soft‑tissue infections. It is indicated for adult patients with infections caused by susceptible Gram‑negative and Gram‑positive organisms.

GNH USA supplies Moxifloxacină Rompharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU GMP standards and is distributed through a secure cold‑chain logistics network.

Moxifloxacin is a fluoroquinolone antibiotic used to treat serious bacterial infections affecting various organ systems.

- Community‑acquired pneumonia: effective treatment of moderate to severe cases caused by susceptible bacteria. - Intra‑abdominal infections: used for complicated infections such as peritonitis and intra‑abdominal abscesses. - Skin and soft‑tissue infections: indicated for severe cellulitis and wound infections when oral therapy is insufficient. - Complicated urinary tract infections: employed in cases of resistant Gram‑negative uropathogens. - Acute bacterial sinusitis: provides therapy for severe sinus infections unresponsive to first‑line agents.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, usually self‑limiting. - Headache: transient cranial discomfort. - Dizziness: occasional vertigo or light‑headedness. - Rash: mild skin erythema. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, may occur without warning. - QT interval prolongation: risk of cardiac arrhythmias. - Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome. - Clostridioides difficile infection: potentially life‑threatening colitis. - Hepatic failure: rare but serious liver injury. - Peripheral neuropathy: persistent sensory deficits.

When using Moxifloxacin injectable, several precautions should be observed to minimize risks.

- Renal impairment: monitor kidney function and adjust therapy as needed. - History of tendon disorders: avoid use in patients with prior tendon injury or tendonitis. - Cardiac risk: assess QT interval before treatment and avoid in patients with known prolongation. - Pregnancy and lactation: prescribe only if benefits outweigh potential risks to the fetus or infant. - Concomitant medications: review for drugs that may increase QT prolongation or interact adversely. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin can interact with other medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Co‑administration with other QT‑prolonging agents (e.g., macrolides, antiarrhythmics): heightened risk of torsades de pointes. - Systemic corticosteroids: increased incidence of tendon rupture. - Concurrent fluoroquinolones: additive toxicity and antagonistic effects.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Theophylline: moxifloxacin can raise plasma theophylline levels, risking toxicity. - Cyclosporine: increased risk of nephrotoxicity when combined. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may augment central nervous system side effects.